Ipamorelin Dosage, As the Studies Recorded It

Read this first

This page describes ipamorelin dosage strictly as it appears in published research — the amounts given to animals or to volunteers inside trials. It is not a guide, and it contains no recommendation for any person. There is a reason for the caution beyond house style: ipamorelin has no approved human dose, because no trial ever established one. The clearest number is its half-life — about two hours in humans, meaning the amount in the blood falls by half roughly every two hours ^[2]. Below you will find the doses used in the human pharmacokinetic study and the failed surgery trial, the doses used in rat and ferret studies, the routes that have been tested, and basic peptide-handling notes. None of it tells you what to do — and the popular CJC-1295 stack protocols have no peer-reviewed human dosing basis at all.

Doses used in human studies

Two human studies define the recorded human exposures. The pharmacokinetic study gave single intravenous infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes, eight volunteers per level — producing dose-proportional kinetics and a single growth-hormone pulse peaking near 40 minutes ^[2]. The Phase 2 ileus trial used 0.03 mg/kg intravenously twice daily for up to seven days in 114 surgical patients — a regimen that missed its efficacy endpoint ^[3].

Both were intravenous and clinician-administered inside controlled studies. Neither establishes a dose for any other use, and there is no published human subcutaneous dosing study at all.

Doses used in animal studies

The animal record is where most ipamorelin dosing data live. The founding pharmacology reported a conscious-pig half-maximal dose of 2.3 nmol/kg ^[1]. The rat bone-growth study used 18, 90, and 450 micrograms per day subcutaneously, split three times daily, for 15 days ^[4]. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally ^[5]. These are species-specific experimental amounts, not human-equivalent figures — animal doses do not translate directly to people, and none of these studies was designed to find a human dose.

Half-life, kinetics, and timing

Ipamorelin's human terminal half-life — the time for blood levels to halve during elimination — is approximately two hours, with clearance of 0.078 L/h/kg and a steady-state distribution volume of 0.22 L/kg ^[2]. The growth-hormone response it triggers is not a plateau but a single discrete pulse, peaking around 40 minutes after dosing and then subsiding ^[2]. In rats, plasma clearance runs roughly five-fold lower than GHRP-6. The short half-life and pulsed response are the pharmacologic facts most often cited to explain why community protocols dose more than once per day — a rationale, not an endorsement.

Routes studied

Ipamorelin has been administered by several routes in research. Intravenous dosing carries the human pharmacokinetic and clinical-trial data and much rodent efficacy work. Subcutaneous dosing appears in rodent bone and body-composition studies and is the dominant route in off-label community use — though, again, with no published human characterisation. Intranasal dosing was studied in rodents at roughly 20% bioavailability; intraperitoneal dosing appears in rodent and ferret studies. Oral dosing works only for engineered ipamorelin-derived analogs (around 10% in dogs) — ipamorelin itself is not orally bioavailable.

How much cjc-1295 ipamorelin should i take

This site does not answer how much cjc-1295 ipamorelin should i take with a number, and no honest source can — there is no validated human dose for the combination. The CJC-1295 + ipamorelin stack rests on the separate single-agent pharmacology of each peptide ^[11], not on any controlled human trial of the pair ^[14]. Community 'stack' protocols circulate widely, but they have no peer-reviewed human dosing basis and are, by definition, anecdotal. What the literature does establish is ipamorelin's two-hour half-life and single-pulse kinetics ^[2] — the pharmacology, not a personal protocol. For dosing decisions, the appropriate source is a qualified clinician, not a website.

How to reconstitute cjc-1295 ipamorelin 5mg

On how to reconstitute cjc-1295 ipamorelin 5mg: ipamorelin is supplied for research as a freeze-dried (lyophilized) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for handling. As a peptide it degrades with heat and with repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a protocol for use in any person. Concentration and volume are handling choices made in a research setting; this site offers no figures for human use.